TIAA CREF Investment Management’s Osiris Therapeutics, Inc. Common Stock OSIR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
Sell
-52,276
Closed -$257K 3140
2016
Q4
$257K Sell
52,276
-13,608
-21% -$69.7K ﹤0.01% 3006
2016
Q3
$327 Hold
65,884
﹤0.01% 2981
2016
Q2
$335K Buy
65,884
+5,209
+9% +$28K ﹤0.01% 3006
2016
Q1
$346K Buy
60,675
+4,121
+7% +$28.8K ﹤0.01% 2887
2015
Q4
$587K Sell
56,554
-2,708
-5% -$36.8K ﹤0.01% 2841
2015
Q3
$1.09M Hold
59,262
﹤0.01% 2523
2015
Q2
$1.15M Buy
59,262
+452
+0.8% +$8K ﹤0.01% 2627
2015
Q1
$1.03M Hold
58,810
﹤0.01% 2601
2014
Q4
$940K Sell
58,810
-9,341
-14% -$125K ﹤0.01% 2681
2014
Q3
$858K Sell
68,151
-4,091
-6% -$58.4K ﹤0.01% 2724
2014
Q2
$1.13M Buy
72,242
+34
+0% +$500 ﹤0.01% 2649
2014
Q1
$948K Sell
72,208
-2,330
-3% -$36.5K ﹤0.01% 2667
2013
Q4
$1.2M Buy
74,538
+6,270
+9% +$99.9K ﹤0.01% 2567
2013
Q3
$1.14M Sell
68,268
-355
-0.5% -$5.25K ﹤0.01% 2543
2013
Q2
$691K Buy
+68,623
New +$721K ﹤0.01% 2804

Other funds holding OSIR

TIAA CREF Investment Management's OSIR Position: Q1 2017 in Review

TIAA CREF Investment Management sold out of Osiris Therapeutics, Inc. Common Stock (OSIR) in Q1 2017, closing a stake of 52,276 shares — an estimated $257K sold.

TIAA CREF Investment Management first reported a position in OSIR in Q2 2013 and held it in 15 quarters. The position peaked at $1.2M in Q4 2013. 11 funds tracked by Wall St. Rank hold OSIR as of Q1 2017.

  • TIAA CREF Investment Management reported no remaining Osiris Therapeutics, Inc. Common Stock position as of Q1 2017 after selling out during the quarter.
  • TIAA CREF Investment Management sold 52,276 Osiris Therapeutics, Inc. Common Stock shares in Q1 2017, an estimated $257K.
  • TIAA CREF Investment Management first reported a position in Osiris Therapeutics, Inc. Common Stock in Q2 2013 and held it in 15 quarters.
  • TIAA CREF Investment Management's Osiris Therapeutics, Inc. Common Stock position peaked at $1.2M in Q4 2013.
  • 11 funds tracked by Wall St. Rank held Osiris Therapeutics, Inc. Common Stock as of Q1 2017.

Based on TIAA CREF Investment Management's 13F filing for Q1 2017, filed 11 May 2017.